Behavioural Intervention
Function Focused Care for Dementia
This trial is testing the efficacy of a new approach to care for older adults with Alzheimer's Disease and Related Dementias (ADRD) that encourages physical activity during hospitalization. The new approach, called Function Focused Care for Acute Care (FFC-AC-EIT), is being tested against standard care (Function Focused Care Education Only, or EO) in 12 hospitals. The primary outcomes being measured are physical activity, function, and participation in function focused care.
Behavioral Intervention
Cognitive Training for Mild Cognitive Impairment
This trial is designed to find the best combination of cognitive training exercises to improve cognitive function in older adults with mild cognitive impairment, and to reduce the risk of dementia.
Potassium Channel Opener
Nicorandil for Hippocampal Sclerosis
This trial is testing nicorandil, a heart medication, to see if it can help elderly patients with Hippocampal Sclerosis of Aging (HS-Aging), a condition often mistaken for Alzheimer's disease. HS-Aging affects many older adults and currently has no specific treatments. Nicorandil may help by improving blood flow, potentially reducing symptoms of dementia. Nicorandil has shown potential as a therapeutic agent for Alzheimer's disease by inhibiting oxidative stress and amyloid-β precursor protein processing.
Popular Filters
Trials for Alzheimer's Disease Patients
Behavioural Intervention
Dysphagia Therapy for Alzheimer's Disease
This trial tests a saliva gel and tongue exercises to help people with Alzheimer's who have trouble swallowing. These patients are at risk of pneumonia because they can't swallow well. The saliva gel keeps their mouth moist, and the exercises make their tongue stronger to help with swallowing.
Behavioural Intervention
Aerobic Exercise for Alzheimer's Disease
This trial tests whether regular aerobic exercise can help prevent dementia in older adults with memory issues. The exercise program aims to improve brain health by boosting blood flow and fitness. Researchers hope to show that this can slow down or prevent cognitive decline.
Trials for Mild Cognitive Impairment Patients
Tyrosine Kinase Inhibitor
TKIs for Dementia
This trial is designed to evaluate the tolerability and potential efficacy of tyrosine kinase inhibitors in patients with mild cognitive impairment or dementia. Baseline and outcome measures utilize validated tests that are appropriate for repeated measures. The study population is sufficiently broad and the conditions of interest are sufficiently prevalent so that recruitment of the projected numbers of subjects is not a limiting factor.
Phase 3 Trials
Monoclonal Antibodies
Investigational Alzheimer's Drugs for Early Onset Alzheimer's Disease
This trial tests two drugs, lecanemab and E2814, in people with a genetic mutation that causes Alzheimer's disease. Lecanemab helps remove harmful protein clumps from the brain, while E2814 prevents harmful protein tangles from forming. The goal is to see if these drugs can slow down or improve symptoms of Alzheimer's.
Monoclonal Antibodies
Gantenerumab for Alzheimer's Disease
This trial will study if treatment with an investigational study drug can prevent or slow the rate of Alzheimer's disease (AD)-causing accumulation of amyloid beta (Aβ). Part 1 will use Aβ positron emission tomography (PET) imaging to determine if treatment with the study drug prevents or slows the rate of Aβ pathological disease accumulation. Part 2 will evaluate the effect of early Aβ plaque reduction/prevention on disease progression by assessing downstream non-Aβ biomarkers of AD.
Behavioural Intervention
Hearing Aid Intervention for Cognitive Decline
This trial is testing if giving hearing aids to older adults with untreated hearing loss can help slow down memory and thinking problems. It compares this to just giving general health advice. The idea is that better hearing keeps the brain active, which might help prevent cognitive decline. Hearing aids have been shown to improve cognitive function and offset declines in neural function in older adults.
Monoclonal Antibodies
Donanemab for Early Alzheimer's Disease
This trial is testing different doses of donanemab, a drug aimed at helping people with early Alzheimer's disease. Donanemab has shown rapid reduction of brain amyloid in early Alzheimer's disease. The study will look at how often and how severely participants experience a side effect involving brain swelling. Researchers also want to find out which patient characteristics might predict this side effect.
Trials With No Placebo
Behavioural Intervention
Dysphagia Therapy for Alzheimer's Disease
This trial tests a saliva gel and tongue exercises to help people with Alzheimer's who have trouble swallowing. These patients are at risk of pneumonia because they can't swallow well. The saliva gel keeps their mouth moist, and the exercises make their tongue stronger to help with swallowing.
Behavioural Intervention
Aerobic Exercise for Alzheimer's Disease
This trial tests whether regular aerobic exercise can help prevent dementia in older adults with memory issues. The exercise program aims to improve brain health by boosting blood flow and fitness. Researchers hope to show that this can slow down or prevent cognitive decline.
Tyrosine Kinase Inhibitor
TKIs for Dementia
This trial is designed to evaluate the tolerability and potential efficacy of tyrosine kinase inhibitors in patients with mild cognitive impairment or dementia. Baseline and outcome measures utilize validated tests that are appropriate for repeated measures. The study population is sufficiently broad and the conditions of interest are sufficiently prevalent so that recruitment of the projected numbers of subjects is not a limiting factor.
View More Related Trials
Frequently Asked Questions
Introduction to dementia
What are the top hospitals conducting dementia research?
When it comes to advancing our understanding and treatment of dementia, several hospitals are leading the charge in clinical trials. In Cleveland, Case Western Reserve University has emerged as a prominent institution with three active trials focused on dementia. Since conducting their first recorded trial in 2019, they have contributed significantly to the field with six completed studies thus far. Similarly, the University of Minnesota in Minneapolis is making a significant impact through its ongoing collaborations on three active dementia trials and nine total trials since their initial research endeavor in 2018.
In Sun City at Banner Sun Health Research Institute, researchers have piloted groundbreaking investigations into dementia for over a decade. With three current clinical trials underway and an impressive sixteen completed studies under their belt since 2009, this institute continues to play a vital role in expanding our knowledge of this complex condition.
Meanwhile, Progressive Medical Research in Port Orange joins the ranks with its dedication to dementia research. Like their counterparts mentioned earlier, they currently conduct three active clinical trials and have made notable contributions through five previous studies since initiating their inaugural trial also back in 2019.
Finally, we look towards Missouri where the University of Missouri holds its own significance regarding dementia research. Though smaller-scale compared to some other institutions mentioned here; two ongoing clinical tests thrive alongside another fascinating aspect that marks them trailblazers around limited resources-three accomplished experiments conducted between timescales starting from early days tracing back until2003.
These hospitals represent beacons of hope for individuals affected by this debilitating condition and serve as pioneers shaping future treatments for better quality-of-life outcomes worldwide.
Which are the best cities for dementia clinical trials?
In the realm of dementia clinical trials, several cities stand out as hubs for research and exploration. Seattle, Washington leads with 13 active trials focused on a range of interventions like Survey-based Patient/Clinician Jumpstart and STAR-VTF. Toronto, Ontario follows closely behind with 9 ongoing studies investigating treatments including Escitalopram and VR&R Therapy. San Francisco, California also showcases its commitment to advancing dementia care through 9 active trials centered around Brain Health Intervention and Cognitive Training. Together, these cities offer individuals affected by dementia access to cutting-edge clinical trials that hold promise for improved understanding and management of this complex condition.
Which are the top treatments for dementia being explored in clinical trials?
Clinical trials for dementia are paving the way for new treatments and hope. Taking center stage is intervention, currently being explored in four active trials dedicated to dementia. Since its first listing in 2013, it has garnered a total of five trials focused on this debilitating condition. Close behind is cognitive training, with two ongoing trials and a history of four all-time dementia studies since its debut in 2019. These innovative approaches hold promise for improving the lives of those affected by dementia, offering glimpses of light amidst the challenges they face.
What are the most recent clinical trials for dementia?
Recent clinical trials bring hope to the field of dementia research, offering potential advancements in diagnosis, treatment, and care. One notable study explores the use of 123I-MIBG scintigraphy as a diagnostic tool for dementia. Another trial investigates the efficacy of Donanemab at dose level 4 in improving cognitive function and slowing disease progression. Additionally, an experimental treatment involving XPro1595 shows promise in addressing symptoms associated with dementia. Predicted Responders is another intriguing trial that aims to identify individuals who are likely to benefit from specific interventions. Finally, a Phase 3 study focuses on hearing intervention (HI) groups and their impact on mitigating cognitive decline related to dementia. These trials present diverse approaches towards understanding and combating this complex condition.
What dementia clinical trials were recently completed?
In the realm of dementia research, several noteworthy clinical trials have recently wrapped up, providing valuable insights into potential treatments. In April 2022, BioXcel Therapeutics Inc. completed a trial examining BXCL501's efficacy in addressing this debilitating condition. Prior to that, Eisai Inc.'s E2027 trial concluded in February 2021, followed by Axsome Therapeutics' AXS-05 study and Woolsey Pharmaceuticals' investigation on Oral Fasudil 90 mg/day both completing in December 2020. Moreover, Athira Pharma's ATH-1017 trial reached its endpoint in November 2020. These trials contribute to our understanding of various therapeutic avenues for dementia treatment and highlight ongoing efforts within the scientific community to combat this challenging disease effectively.